A nicotine lozenge is an approved drug with an indication, a dosing schedule and a daily maximum; a nicotine pouch is a tobacco product with none of those. The split comes from one definition with one carve-out — 21 U.S.C. § 321(rr) — and not from the chemistry, because three pouch brands use the same nicotine polacrilex resin the lozenge does.
People reach for this comparison because the two things look so similar in the mouth: a small object you park against your gum and let dissolve, releasing nicotine across the buccal mucosa. Almost everything else about them diverges, and the divergence is legal rather than physical. Here is the asymmetry, from the statutes, the label and the measurements.
One definition, one carve-out
The whole structure sits in a single subsection of the Food, Drug, and Cosmetic Act, read as codified. In order:
“(rr)(1) The term “tobacco product” means any product made or derived from tobacco,” “or containing nicotine from any source, that is intended for human consumption,” “including any component, part, or accessory of a tobacco product”
“(2) The term “tobacco product” does not mean an article that is a drug under subsection (g)(1),” “a device under subsection (h), or a combination product described in section 353(g) of this title.”
“(3) The products described in paragraph (2) shall be subject to subchapter V of this chapter.”
Paragraph (1) pulls a tobacco-free pouch in, because it contains nicotine from any source. Paragraph (2) pushes the lozenge out, because it is a drug. Paragraph (3) sends the lozenge to the drugs subchapter. These are not two regimes that happen to differ; they are one definition and its express exception.
What makes something a drug, in turn, is intended use: subsection (g)(1) covers “articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals”. So a cessation claim is what moves a product across the line — not an ingredient, not a shape.
Worth noting how recent all this is. The phrase “, or containing nicotine from any source,” was inserted into (rr)(1) by Pub. L. 117-103 § 111(a)(1) in 2022. Before that, a tobacco-free synthetic-nicotine pouch was arguably neither a drug nor a tobacco product. The regime looks improvised because it is three and a half years old.
Head to head
| Nicotine lozenge (OTC) | Nicotine pouch | |
|---|---|---|
| Legal category | Drug. Excluded from “tobacco product” by § 321(rr)(2) | Tobacco product under § 321(rr)(1) |
| Authorisation route | Approved application under FD&C Act § 505 (NDA or ANDA) | Premarket tobacco product application, § 387j |
| Approval standard | Safe and effective for its labelled indication | “appropriate for the protection of the public health” |
| Indication | “Stop smoking aid” | None permitted |
| Dosing schedule | 12 weeks; 1 every 1–2 h, then 2–4 h, then 4–8 h | None published by anyone |
| Daily maximum | 20 lozenges; and not more than 5 in 6 hours | None published by anyone |
| Strengths | 2 mg and 4 mg | 2 to 11 mg on FDA’s authorised list |
| Nicotine form | Nicotine polacrilex (ion-exchange resin) | Salt, freebase, or polacrilex depending on brand |
| Nicotine addiction warning | None on the label | Required on 30% of two display panels |
| Federal excise tax | None under chapter 52 | None, if tobacco-free |
| Minimum age | 18, from the approved labelling | 21, by statute, since 20 December 2019 |
The lozenge has a label, and that is the real difference
Everything in the left-hand column above comes from an FDA-approved label. I used the full-size NICORETTE nicotine polacrilex lozenge, Haleon US Holdings LLC, ANDA 077007, effective 25 April 2025. Its stated purpose is “Stop smoking aid”; its use is “reduces withdrawal symptoms, including nicotine craving, associated with quitting smoking”. Those are FDA-approved words for that product, and I am quoting them as such — a nicotine pouch may not say either of them.
The label picks your strength from a behavioural question, not from a milligram preference: “if you smoke your first cigarette within 30 minutes of waking up,” use the 4 mg; “if you smoke your first cigarette more than 30 minutes after waking up, “ use the 2 mg. Then it tapers over twelve weeks, with the interval widening from one lozenge every one to two hours, to every two to four, to every four to eight. It caps use at both ends: “do not use more than 5 lozenges in 6 hours. Do not use more than 20 lozenges per day.” and “to improve your chances of quitting, use at least 9 lozenges per day for the first 6 weeks”.
It tells you how to hold it — “place the lozenge in your mouth and allow the lozenge to slowly dissolve (about 20 – 30 minutes). Minimize swallowing.”, and in the same printed bullet, in bold, “Do not chew or swallow lozenge.” It tells you not to eat or drink for fifteen minutes beforehand. It lists conditions that warrant asking a doctor first, including “a sodium-restricted diet” — the full-size lozenge contains “sodium 17 mg” each — and “heart disease, recent heart attack, or irregular heartbeat. Nicotine can increase your heart rate.” It even tells you it is a medicine: “nicotine lozenge is a medicine and must be used a certain way to get the best results”.
No pouch has an equivalent of any of that, and the absence is not an oversight. I searched FDA’s authorised nicotine pouch list — the page that says “There are 67 nicotine pouch products authorized by the FDA. These are the only nicotine pouch products that may be lawfully sold in the United States.”, content current 30 October 2026 — for “dose”, “dosing”, “per day”, “maximum”, “interval”, “hours”, “directions”, “craving” and “cessation”. Every one returns zero. The same search on FDA’s ZYN authorisation announcement returns zero. The authorisation route does not produce a dose, because it never asked for one: the statutory test at § 387j(c)(2)(A) turns on whether “there is a lack of a showing that permitting such tobacco product to be marketed would be appropriate for the protection of the public health”. No indication, no efficacy finding, no labelled dose.
One thing the lozenge label also lacks, and it surprised me: any pharmacokinetic reasoning. There is no half-life, no peak concentration and no PK section in it. The interval is a condition of an approved application, asserted rather than derived. I go into what the half-life does and does not justify in nicotine half-life and how to space your pouches.
What each one is allowed to claim
The mechanism that keeps a pouch from claiming anything therapeutic is a short chain of provisions, each quotable. A cessation claim makes the article a drug under § 321(g)(1)(B); § 321(rr)(2) then removes it from “tobacco product”; § 321(rr)(3) subjects it to the drugs subchapter; and 21 CFR 310.544(b) closes it off: “Any OTC drug product that is labeled, represented, or promoted as a smoking deterrent is regarded as a new drug” “within the meaning of section 201(p) of the Federal Food, Drug, and Cosmetic Act (the act),” “for which an approved application or abbreviated application under section 505 of the act and part 314 of this chapter is required for marketing.” A pouch marketed for quitting would need a drug application, not a tobacco one.
FDA says the narrower version of this plainly in its own words, about ZYN: “the authorization does not allow the company to make reduced risk claims about the authorized products, which would require a modified risk tobacco product application.”
A modified-risk order is possible in principle, and exactly one smokeless product family has one — for snus, not for any pouch. FDA’s technical project lead review of the renewal records the authorised wording in two fragments, because it line-wraps in the document: “Using General Snus instead of cigarettes puts you at a lower risk of mouth” “cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” Read that carefully. It is a closed list of six named conditions; it is conditional on substitution, instead of cigarettes; and the finding behind it is about exclusive use. It is not a cessation claim, and it does not attach to pouches.
Interestingly, the MRTP statute itself draws the line this article is about. 21 U.S.C. § 387k(g)(4)(D) requires FDA to weigh “the risks and benefits to persons from the use of the tobacco product that is the subject of the application as compared to the use of products for smoking cessation approved under subchapter V to treat nicotine dependence” — the tobacco regime measuring itself against the drug regime, by statute.
The chemistry is not the divider
I expected the nicotine form to separate them cleanly, and it does not. The best non-industry analysis is Page and colleagues, Nicotine & Tobacco Research (2026), supported by the National Cancer Institute: “Research reported in this publication was supported by the National Cancer Institute (NCI) of the National Institutes of Health under Award Numbers U54 CA228110 and P01 CA200512.” It describes itself as “This is the first non-industry study to compare nicotine content, release, form, and select flavoring composition between multiple ONPs and OTPs.” The senior author declares a Pfizer research grant and a Johnson & Johnson advisory board role outside the work.
Its finding on manufacturer disclosures is the one that breaks the tidy story: “ONP brands LUCY, NIC-S, and Rogue disclosed nicotine polacrilex, where nicotine is bound to an ion exchange resin and delivered via an aqueous extraction, similar to therapeutic nicotine gums.” That is the lozenge’s own chemical form, in a tobacco product. Two qualifications matter: none of those three brands appears on FDA’s authorised list, so in the United States they are unauthorised products; and the authorised brands the study examined went the other way — “ZYN and on! further indicated that nicotine in these products was salt-based.” and “ZYN specifically disclosed the use of nicotine bitartrate dihydrate.”
The same study shows how wide the pouch field is on the variable that governs absorption. Average pH ranged from “7.0 (VELO 4 mg) to 9.0 (FRĒ 15 mg)”, corresponding to “0.9% to 89.7% freebase nicotine.” Mechanistically, “The buccal mucosa in the mouth better absorbs freebase nicotine than highly protonated nicotine.” and, as a counterweight, “Alternatively, an increasing proportion of freebase nicotine is associated with more irritation, and so duration of use will also impact nicotine delivery and abuse potential.” Freebase fractions were calculated from the Henderson–Hasselbalch equation “(using a nicotine pKa of 8.01)” — worth stating because 8.01 circulates online as a pouch pH, and it is a dissociation constant.
The lozenge’s own alkali is on the label, in the inactive ingredients: potassium bicarbonate and sodium carbonate in the full-size product. The label gives no pH figure.
So the dosage form does not decide the category either. One 2007 study measured the drug Commit lozenge in the same protocol as Ariva, Revel and Stonewall — compressed-tobacco oral products sold in lozenge form and regulated as tobacco products. “Lozenge” is a shape.
How fast each one works, and what has not been published
For pouches, the usable dataset is McEwan and colleagues (2022), in 35 habitual users. It is industry work: “The study was supported by British American Tobacco (Investments) Limited, the manufacturer of Lyft and Velo smokeless oral nicotine pouches.” Peak plasma nicotine ran from 11.9 to 18.4 ng/mL across five pouches used for 60 minutes, against 13.9 for a cigarette, and time to peak was 60 to 65 minutes against 7 for the cigarette. The headline finding is that the number on the can does not predict delivery: “Plasma nicotine concentration was not associated with the nicotine contents of the NPs.”
For the lozenge, I have to report a gap rather than a figure. The canonical pharmacokinetic study is Choi and colleagues, Nicotine & Tobacco Research (2003), and it is not openly deposited; its publisher does not serve automated requests, so I could not read the paper and will not quote absolute numbers from a secondary source. The abstract gives relative figures only: the single-dose studies “consistently demonstrated 8%-10% higher maximal plasma concentrations and 25%-27% higher AUC values (area under the concentration-time curve) from the lozenges compared with the gums at the 2- and 4-mg dose levels, probably owing to the residual nicotine retained in the gum.” No funding statement is present in that record, and I am not going to assert one. One finding in it is worth printing because it supports the label: “Administration of the lozenge contrary to the label-specified instructions for use did not lead to a faster or higher absorption of nicotine.”
What about a direct comparison? Two head-to-head pharmacokinetic studies of pouches against lozenges are on the public registry, both completed, both industry-sponsored, and neither has published anything. NCT04755348, sponsored by British American Tobacco (Investments) Limited, compared two 4 mg pouches against four 2 mg lozenges in 36 people and completed on 25 March 2021. NCT06171490, sponsored by Philip Morris Products S.A., compared two pouch variants against a 4 mg lozenge and a 4 mg gum in adult smokers and completed on 20 March 2024. Neither has a posted results section, and neither appears in PubMed or PMC. The comparison has been made twice and reported zero times.
Tax, warnings and who may buy
Federal excise tax reaches neither. Every chargeable category in 26 U.S.C. § 5702 is a tobacco category — “”Tobacco products” means cigars, cigarettes, smokeless tobacco, pipe tobacco, and roll-your-own tobacco.”, with smokeless tobacco defined as “any snuff or chewing tobacco” and snuff as “any finely cut, ground, or powdered tobacco that is not intended to be smoked.” The word “nicotine” occurs exactly once in all 26,143 bytes of that section, in a 1958 amendment note about fertiliser and insecticide. The rate lives next door, in § 5701(e)(1): “On snuff, $1.51 per pound and a proportionate tax at the like rate on all fractional parts of a pound.” Snus pays that; a tobacco-free pouch pays nothing federal; and the lozenge is outside chapter 52 altogether, being a drug.
States diverge, and the drug exemption is not automatic — each legislature has to write it. Washington’s definition is broad enough to catch synthetic nicotine in any form, reaching “any other product, regardless of form, that contains tobacco or nicotine, whether derived from tobacco or created synthetically, and is intended for human consumption or placement in the oral or nasal cavity or absorption into the human body by any other means”, and then carves the drug out by hand. Minnesota’s base is tobacco-derived, and its nicotine extension covers solutions rather than pouches; it exempts “any tobacco product that has been approved by the United States Food and Drug Administration for sale as a tobacco cessation product”. I have not found Minnesota Revenue guidance confirming how it treats a tobacco-free pouch, so I am reporting the text and not the conclusion.
On warnings the asymmetry reverses. 21 CFR 1143.3(a)(1) requires covered tobacco products to carry, wrapped in the regulation’s own quotation marks, “WARNING: This product contains nicotine. Nicotine is an addictive chemical.” and requires that “the warning area must comprise at least 30 percent of each of the principal display panels”. The lozenge and gum labels contain no nicotine-addiction warning at all: “addictive” returns zero hits in both. The drug devotes none of its packaging to that statement; the tobacco product devotes nearly a third of two panels to it.
Age. For the pouch it is statutory: “It shall be unlawful for any retailer to sell a tobacco product to any person younger than 21 years of age.” — 21 U.S.C. § 387f(d)(5), added by Pub. L. 116-94 § 603(a)(2) and effective 20 December 2019. For the lozenge the 21 does not apply, because § 321(rr)(2) excludes a drug, and “21 years” appears nowhere in either label. The lozenge’s 18 comes from the approved labelling instead: “if you are under 18 years of age, ask a doctor before use.” in the directions, and on the carton “not for sale to those under 18 years of age”, “proof of age required” and “not for sale in vending machines or from any source where proof of age cannot be verified”. FDA’s own consumer page puts it the same way: “Over-the-counter NRTs are approved for sale to people age 18 and older.” I could find no federal statute or regulation setting a purchase age for an OTC nicotine replacement drug; the number lives in the label.
One more legal oddity worth knowing
A tobacco-free pouch is a tobacco product and is simultaneously not smokeless tobacco. 21 U.S.C. § 387(18) defines smokeless tobacco as “any tobacco product that consists of cut, ground, powdered, or leaf tobacco and that is intended to be placed in the oral or nasal cavity.” A pouch with no tobacco in it fails that test, and fails the parallel test in § 5702(m) too. So the pouch sits inside one statutory category and outside another, and the word “tobacco” in “tobacco product” no longer describes the thing it covers. That is the cleanest way I know to summarise why this comparison is confusing: the categories are legal artefacts, and the products stopped matching them in 2022.
FAQ
Is a nicotine pouch stronger than a 4 mg lozenge?
Not answerable from published data. The authorised pouch range is 2 to 11 mg, but the measured peak concentrations from pouches were not associated with the milligram figure at all, and no absolute lozenge peak is openly retrievable. Two registered studies compared them directly and neither has published.
Why does a lozenge have a dosing schedule and a pouch does not?
Because a lozenge is approved as a drug for a stated indication, and a dose is part of what gets approved. A pouch is authorised as a tobacco product on a public-health test that contains no dose, no indication and no efficacy finding.
Can a nicotine pouch say it helps you quit?
No. A cessation claim would make it a drug under § 321(g)(1)(B), removing it from the tobacco-product definition and requiring a drug application under 21 CFR 310.544(b). FDA has also stated that pouch authorisation “does not allow the company to make reduced risk claims” without a separate modified-risk application.
Are pouches and lozenges taxed differently?
Not federally — neither pays federal tobacco excise, though for different reasons. At state level it varies, and the exemption for an approved drug has to be legislated explicitly, which not every state has done in the same terms.
Do they contain the same kind of nicotine?
Sometimes. The lozenge uses nicotine polacrilex, an ion-exchange resin complex, and three pouch brands disclose the same form. FDA’s authorised pouch brands disclose salt-based nicotine instead; ZYN names nicotine bitartrate dihydrate.
Sources
- 21 U.S.C. § 321, definitions, including (rr) and (g)(1). US Government Publishing Office. Read 7 November 2026.
- 21 U.S.C. § 387 (definitions), § 387f (minimum age of sale), § 387j (premarket review) and § 387k (modified risk tobacco products). § 387 · § 387f · § 387j · § 387k. Read 7 November 2026.
- 26 U.S.C. § 5701 and § 5702, tobacco excise rates and definitions. § 5701 · § 5702. Read 7 November 2026.
- 21 CFR 310.544 and 21 CFR 1143.3, via the eCFR versioner API at 1 January 2026. § 310.544 · part 1143. Read 7 November 2026.
- NICORETTE (nicotine polacrilex) lozenge, Haleon US Holdings LLC, ANDA 077007, effective 25 April 2025. DailyMed setid ffeb8286-860d-49f5-8df3-724afb4aaad8. Companion gum label: setid a0206139-59c6-44c3-963c-8cb5f2d69075. Read 7 November 2026.
- US Food and Drug Administration, Nicotine Pouch Products Authorized by the FDA, content current 30 October 2026. fda.gov. Read 7 November 2026.
- US Food and Drug Administration, FDA Authorizes Marketing of 20 ZYN Nicotine Pouch Products After Extensive Scientific Review, 16 January 2025. fda.gov. Read 7 November 2026.
- US Food and Drug Administration, Technical Project Lead Review of MRTPA(s), Swedish Match U.S.A. Inc., General Snus renewal, received 17 July 2023. fda.gov/media/183418. Read 7 November 2026.
- US Food and Drug Administration, Want to Quit Smoking? FDA-Approved and FDA-Cleared Cessation Products Can Help, content current 21 July 2022. fda.gov. Read 7 November 2026.
- Page MK, Leigh NJ, Block AC, Marrano PH, Travers MB, Adrover JE, Maley GE, Koenig LA, Salem EM, Heldwein SD, Goniewicz ML. Comparison of Nicotine and Selected Flavoring Contents Between Tobacco-Free and Tobacco-Containing Oral Pouches. Nicotine & Tobacco Research, 2026. NCI-funded. PMC12824957. Read 7 November 2026.
- McEwan M, Azzopardi D, Gale N, Camacho OM, Hardie G, Fearon IM, Murphy J. A Randomised Study to Investigate the Nicotine Pharmacokinetics of Oral Nicotine Pouches and a Combustible Cigarette. Eur J Drug Metab Pharmacokinet, 2022. BAT-funded. PMC8917032. Read 7 November 2026.
- Choi JH et al. Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine & Tobacco Research, 2003; PMID 14577980. Abstract only — the full text is not openly deposited and the publisher does not serve automated requests. PubMed record. Read 7 November 2026.
- Kotlyar M et al. Nicotine pharmacokinetics and subjective effects of three potential reduced exposure products, moist snuff and nicotine lozenge. Tobacco Control, 2007. Abstract-only deposit. PMC2598476. Read 7 November 2026.
- ClinicalTrials.gov: NCT04755348 (British American Tobacco (Investments) Limited, completed 25 March 2021) and NCT06171490 (Philip Morris Products S.A., completed 20 March 2024). Neither has posted results. Read 7 November 2026.
- Minnesota Statutes § 297F.01. revisor.mn.gov. Washington RCW 82.26.010. app.leg.wa.gov. Both read 7 November 2026.
Last verified: 7 November 2026. Related reading: nicotine pouches explained, nicotine pouch absorption, pouches vs snus and the master ranking. If stopping nicotine is the aim, what the evidence says is the page to read, and a clinician is a better source than any of us. The same extraction-against-absorption arithmetic applied to tobacco snus is set out in how much nicotine is absorbed from a snus portion.
